For the quarter ended December 2025, Amgen (AMGN) reported revenue of $9.87 billion, up 8.6% over the same period last year. EPS came in at $5.29, compared to $5.31 in the year-ago quarter.
The reported revenue represents a surprise of +4.23% over the Zacks Consensus Estimate of $9.47 billion. With the consensus EPS estimate being $4.76, the EPS surprise was +11.18%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Amgen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Product Sales- BLINCYTO- U.S.: $270 million versus $283.5 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +10.2% change.
- Product Sales- KYPROLIS- ROW: $111 million versus $130.37 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -18.4% change.
- Product Sales- Repatha- U.S.: $517 million compared to the $451.25 million average estimate based on six analysts. The reported number represents a change of +64.1% year over year.
- Product Sales- Repatha- ROW: $353 million versus $360.19 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +21.3% change.
- Revenue- Other revenues: $499 million compared to the $396.39 million average estimate based on eight analysts. The reported number represents a change of +34.9% year over year.
- Revenue- Product sales: $9.37 billion versus the eight-analyst average estimate of $9.09 billion. The reported number represents a year-over-year change of +7.5%.
- Product Sales- Otezla- Total: $625 million versus the seven-analyst average estimate of $621.09 million. The reported number represents a year-over-year change of +0.2%.
- Product Sales- KYPROLIS- Total: $351 million versus the seven-analyst average estimate of $362.31 million. The reported number represents a year-over-year change of -5.7%.
- Product Sales- BLINCYTO- Total: $413 million versus $435.33 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +8.4% change.
- Product Sales- Repatha- Total: $870 million versus $811.51 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +43.6% change.
- Product Sales- XGEVA- Total: $447 million versus $453.76 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a -20.3% change.
- Product Sales- Prolia- Total: $1.05 billion versus $974.58 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a -9.5% change.
View all Key Company Metrics for Amgen here>>>
Shares of Amgen have returned +7.5% over the past month versus the Zacks S&P 500 composite's +1.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amgen Inc. (AMGN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
